BOSTON SCIENTIFIC CORP
www.bostonscientific.comAI Executive Summary
AI-powered analysis of 10-Q filing content
Boston Scientific's Q3 2026 results were materially impacted by a cybersecurity incident identified on August 25, 2026, which disrupted manufacturing and order fulfillment, causing Q3 net income to fall 22.9% year-over-year despite modest net sales growth of 1.5%. While nine-month results show stronger growth (6.7% net sales, 27.1% net income) aided by a discrete tax benefit, the company faces compounding headwinds including increased Electrophysiology competition, LAAC/WATCHMAN market deceleration, higher litigation charges, and ongoing ERP implementation risks.
Red Flags Detected (9)
Material cybersecurity incident (Aug 25, 2026) disrupted manufacturing, order processing, and shipping, directly impacting Q3 financial results
Cash and cash equivalents dropped sharply from $1,965M to $609M (69% decline) from Dec 2025 to Sep 2026
Q3 net income attributable to shareholders fell 22.9% YoY ($755M to $582M)
6 more red flags detected
Key Takeaways
Q3 2026 profitability significantly impaired by one-time cybersecurity disruption despite revenue growth
Nine-month performance remains solid, aided by a one-time tax benefit, masking underlying Q3 weakness
3 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.